Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 12,238 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Behavior Problem, Development Delay, Emotional Disturbance, Family Conflict
Interventions: Family Nurture Intervention, Nutrition and Play Intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 24 Months to 54 Months
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Cos Cob, Connecticut

Conditions: Facial Angiofibroma, Tuberous Sclerosis
Interventions: rapamycin, placebo; Drug
Lead sponsor: Dermatology Specialties Limited Partnership; Industry
Eligibility: 6 Years to 65 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Phoenix, Arizona • La Jolla, California • St. Petersburg, Florida + 3 more

Conditions: Healthy Volunteers
Interventions: NPT520-34 (125 mg), Placebos (125 mg); Drug
Lead sponsor: Neuropore Therapies Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Alagille Syndrome
Interventions: LUM001, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 12 Months to 18 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Anxiety Generalized
Interventions: MM120, Placebo; Drug · Other
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 22
States / cities: Little Rock, Arkansas • Irvine, California • La Jolla, California + 18 more

Conditions: Prostate Cancer Metastatic
Interventions: [68Ga]-PSMA-R2; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 2 more

Conditions: Duchenne Muscular Dystrophy
Interventions: NS-050/NCNP-03, Placebo; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 4 Years to 15 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions: PC2: Primary Care Connect; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Healthy Volunteer, Psoriasis
Interventions: ABBV-547, ABBV-547 Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Bryant, Arkansas • Anaheim, California + 15 more

Conditions: Breast Cancer
Interventions: Bevacizumab, Standard adjuvant chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 44
States / cities: Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 40 more

Conditions: Healthy Participants
Interventions: AZD5004, Itraconazole, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gastrostomy, Gastrostomy Complications, Pediatric Disorder, Ultrasound
Interventions: Percutaneous Ultrasound Gastrostomy; Device
Lead sponsor: CoapTech; Industry
Eligibility: 0 Years to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New York, New York • Philadelphia, Pennsylvania

Conditions: Ketogenic Dieting, Ketoses, Metabolic, Ketosis
Interventions: Well-formulated Ketogenic Diet; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 30 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 973 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 5
States / cities: Concord, North Carolina • Davidson, North Carolina • Durham, North Carolina + 2 more

Conditions: Osteoarthritis, Knee
Interventions: JointStem, Placebo Control; Drug · Other
Lead sponsor: Nature Cell Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: El Cajon, California • La Mesa, California • Napa, California + 2 more

Conditions: Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, Myelodysplastic Syndromes
Interventions: Decitabine, Ruxolitinib, Donor Lymphocyte Infusion (DLI); Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 12 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Minneapolis, Minnesota • St Louis, Missouri • Rochester, New York

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
Interventions: EP2101; Biological
Lead sponsor: Epimmune; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 8
States / cities: Los Angeles, California • Orlando, Florida • Albany, New York + 5 more

Conditions: Prostatic Neoplasm
Interventions: AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 7 more

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution; Drug
Lead sponsor: Aerpio Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Austin, Texas • Dallas, Texas

Conditions: Anaemia
Interventions: Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more

Conditions: Neurofibromatosis Type 1
Interventions: Not listed
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: 3 Years to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypertension, Glaucoma, Open-Angle
Interventions: Placebo, RO5093151; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Morrow, Georgia • High Point, North Carolina • Mt. Pleasant, South Carolina

Conditions: Multiple Myeloma
Interventions: Nivolumab, DC/myeloma fusions/GM-CSF; Drug · Biological
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Morton's Neuroma
Interventions: CNTX-4975; Drug
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • El Cajon, California + 7 more

Search by objective public record fields.

Family Nurture Intervention, A Group Model in Connecticut

Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

NS-050/NCNP-03 in Boys With DMD (Meteor50)

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

Pediatric Percutaneous Ultrasound Gastrostomy Technique

Ketogenic Diet Health and Longevity

The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort

A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients

A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma

Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)